Arrayit Pursuing PMA from FDA for OvaDx

While the pre-market approval route is more stringent than the 510(k) pathway and is for devices with the highest risk to patients, the company said it would be the most appropriate strategy for its ovarian cancer test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.